Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Asprosin and miRNA Expression in Young Women With Metabolic Syndrome (ASPRO-MetS)

3 listopada 2026 zaktualizowane przez: Małgorzata Kantorowicz, University of Applied Sciences in Nowy Targ

Association Between Serum Asprosin Concentration and Expression of Selected miRNAs With Risk Factors and Components of Metabolic Syndrome in Young Women: Diagnostic Perspectives

Metabolic syndrome is a major risk factor for cardiovascular disease and type 2 diabetes, and its prevalence in young adults is increasing. Early identification of individuals at risk may improve prevention strategies. This observational, cross-sectional case-control study investigates the relationship between serum asprosin concentration, the expression of six selected circulating microRNAs, and the components and risk factors of metabolic syndrome in young women aged 18 to 35 years. Two equally sized groups will be compared: women meeting NCEP ATP III criteria for metabolic syndrome and healthy age-matched controls. Participants attend a single study visit during which fasting blood samples, anthropometric and body composition measurements, blood pressure, and validated questionnaires assessing physical activity, diet, sleep quality, perceived stress, and quality of life are collected. The study aims to determine whether asprosin and the selected microRNA profile have diagnostic value as biomarkers of metabolic syndrome in this population.

Przegląd badań

Status

Rekrutacyjny

Warunki

Interwencja / Leczenie

Szczegółowy opis

Background. Metabolic syndrome is a complex disorder characterized by the coexistence of abdominal obesity, hypertension, dyslipidemia, and impaired glucose metabolism, resulting in an increased risk of cardiovascular disease and type 2 diabetes mellitus. Although established diagnostic criteria exist, there is an ongoing need for novel biomarkers that may improve early detection and clarify the pathophysiological mechanisms involved, particularly in young adults, in whom the condition remains under-investigated.

Asprosin is a fasting-induced adipokine implicated in glucose metabolism, insulin resistance, and obesity. Circulating microRNAs are considered promising molecular biomarkers involved in metabolic regulation and inflammatory pathways. Brain-derived neurotrophic factor (BDNF) and cortisol are additional candidate mediators linking metabolic, psychological, and sleep-related factors.

Objectives. The primary objective is to determine whether serum asprosin concentration and the expression of six selected circulating microRNAs (miR-15a-5p, miR-197-3p, miR-23a-3p, miR-21-5p, miR-146a-5p, miR-223-3p) differ between young women with metabolic syndrome and healthy age-matched women. Secondary objectives are to compare the prevalence of individual metabolic syndrome components, body composition, anthropometric, insulin resistance and atherogenic indices, physical activity, diet, sleep quality, perceived stress, and health-related quality of life between the groups, and to assess correlations between asprosin, the microRNA profile, and these variables.

Design and participants. A total of 110 women aged 18 to 35 years will be enrolled into two equally sized groups: women with metabolic syndrome without other comorbidities requiring continuous pharmacotherapy (MetS, n=55) and healthy women (CON, n=55). Sample size was calculated using G*Power 3.1.9.7; assuming a two-tailed independent-samples comparison, alpha = 0.05, effect size d = 0.5, and power = 0.80, the minimum required sample is 51 participants per group. Recruitment is continuous and conducted among young women in the Podhale region and the Malopolska Province, primarily in the academic community.

Procedures. Eligibility is screened via an online form. Eligible participants attend a single study visit of approximately 90 minutes at the Institute of Medicine of the University of Applied Sciences in Nowy Targ. After written informed consent, the following are performed: fasting venous blood collection (18 mL, antecubital vein, vacuum system, by qualified medical personnel); blood pressure measurement; anthropometric measurements (body height, body mass, waist, abdominal and hip circumference) and body composition assessment by bioelectrical impedance analysis (BIA); and completion of validated questionnaires - International Physical Activity Questionnaire (IPAQ) and 7-day Physical Activity Recall (7day-PAR), Pittsburgh Sleep Quality Index (PSQI), Perceived Stress Scale (PSS-10), Food Frequency Questionnaire (FFQ) or KomPAN together with the Fitatu dietary application, and the Short Form-36 Health Survey (SF-36).

Laboratory analyses performed immediately in a certified external laboratory: complete blood count, fasting glucose, glycated hemoglobin, insulin, and lipid profile. Plasma is separated by centrifugation at 2500 RCF for 15 minutes, aliquoted, and stored at -80 degrees C until batch analysis of asprosin, BDNF, cortisol, and the microRNA panel.

Metabolic syndrome diagnosis. Made by a physician according to NCEP ATP III criteria for women, requiring at least three of five components: triglycerides greater than 150 mg/dL; HDL cholesterol below 50 mg/dL; blood pressure greater than 130/85 mmHg or antihypertensive treatment; fasting glucose greater than 100 mg/dL or previously diagnosed diabetes; waist circumference greater than 88 cm.

Derived indices. BMI, WHR, WHtR, A Body Shape Index (ABSI), Hip Index (HI), Body Adiposity Index (BAI), Visceral Adiposity Index (VAI), Lipid Accumulation Product (LAP), HOMA-IR, QUICKI, METS-IR, triglyceride-glucose index (TyG), Castelli Risk Index I and II (CRI-I, CRI-II), and Atherogenic Index of Plasma (AIP).

Statistical analysis. Distribution of variables will be assessed using the Shapiro-Wilk test. Between-group comparisons will use the independent-samples t-test or the Mann-Whitney U test as appropriate. Correlations will be assessed using Pearson or Spearman coefficients. Statistical significance will be set at p less than 0.05.

All participants will receive their individual results. Data will be anonymized before analysis and scientific use.

Typ studiów

Obserwacyjny

Zapisy (Szacowany)

110

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

  • Nazwa: Maciej Filipowski, M.D.
  • Numer telefonu: +48 (18) 26-10-726
  • E-mail: ip@ans-nt.edu.pl

Lokalizacje studiów

  • Polska
    • Lesser Poland Voivodeship
      • Nowy Targ, Lesser Poland Voivodeship, Polska, 34-400
        • Rekrutacyjny
        • Institute of Medicine, University of Applied Sciences in Nowy Targ, Kokoszków 71, 34-400 Nowy Targ, Poland
        • Kontakt:
        • Kontakt:
        • Pod-śledczy:
          • Magdalena Więcek, Professor / Full Professor
        • Główny śledczy:
          • Małgorzata Kantorowicz, Ph. D.

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 35 lat (Dorosły)

Akceptuje zdrowych ochotników

Tak

Płeć kwalifikująca się do nauki

Kobieta

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

Women aged 18 to 35 years recruited from the general and academic population of the Podhale region and the Malopolska Province, Poland, through university websites, e-mail, social media, local press, printed posters and leaflets, and information meetings. Eligibility is screened using an online questionnaire. Enrolled participants form two equally sized groups: women diagnosed with metabolic syndrome according to NCEP ATP III criteria and healthy women of comparable age.

Opis

Inclusion Criteria:

  • Female sex
  • Age 18 to 35 years
  • Regular menstrual cycle
  • Not engaged in competitive sports training in any discipline
  • Non-smoker
  • No alcohol abuse
  • No continuous pharmacotherapy, with the exception of treatment for diabetes and/or antihypertensive treatment; no use of hormonal contraception
  • Written informed consent for study participation and processing of personal data

Exclusion Criteria:

  • Age outside the range of 18 to 35 years
  • Irregular menstrual cycle
  • Pregnancy or breastfeeding
  • Continuous pharmacotherapy for indications other than diabetes and/or hypertension, including any form of hormonal contraception (oral, transdermal, vaginal, implant, injectable or intrauterine)
  • Competitive sports training in any discipline
  • Current smoking
  • Alcohol abuse
  • Lack of written informed consent for study participation and processing of personal data

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Modele obserwacyjne: CASE_CONTROL
  • Perspektywy czasowe: CROSS_SECTIONAL

Kohorty i interwencje

Grupa / Kohorta
Interwencja / Leczenie
Metabolic Syndrome Group (MetS)

Women aged 18-35 years meeting NCEP ATP III criteria for metabolic syndrome (at least three of five components: triglycerides greater than 150 mg/dL; HDL cholesterol below 50 mg/dL; blood pressure greater than 130/85 mmHg or antihypertensive treatment; fasting glucose greater than 100 mg/dL or previously diagnosed diabetes; waist circumference greater than 88 cm), with no other comorbidity requiring continuous pharmacotherapy. Target n=55.
Test diagnostyczny: Biomarker panel (asprosin, microRNA, BDNF, cortisol)

Fasting venous blood collection for measurement of serum asprosin, BDNF and cortisol concentrations, and expression of six circulating microRNAs (miR-15a-5p, miR-197-3p, miR-23a-3p, miR-21-5p, miR-146a-5p, miR-223-3p), in addition to complete blood count, glucose, glycated hemoglobin, insulin, and lipid profile.

Inny: Clinical and questionnaire assessment

Blood pressure measurement, anthropometric measurements and bioelectrical impedance body composition analysis, and completion of validated questionnaires (IPAQ, 7day-PAR, PSQI, PSS-10, FFQ/KomPAN with the Fitatu application, SF-36).
Control Group (CON)

Healthy women aged 18-35 years not meeting NCEP ATP III criteria for metabolic syndrome, matched for age, not receiving continuous pharmacotherapy. Target n=55.
Test diagnostyczny: Biomarker panel (asprosin, microRNA, BDNF, cortisol)

Fasting venous blood collection for measurement of serum asprosin, BDNF and cortisol concentrations, and expression of six circulating microRNAs (miR-15a-5p, miR-197-3p, miR-23a-3p, miR-21-5p, miR-146a-5p, miR-223-3p), in addition to complete blood count, glucose, glycated hemoglobin, insulin, and lipid profile.

Inny: Clinical and questionnaire assessment

Blood pressure measurement, anthropometric measurements and bioelectrical impedance body composition analysis, and completion of validated questionnaires (IPAQ, 7day-PAR, PSQI, PSS-10, FFQ/KomPAN with the Fitatu application, SF-36).

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Serum asprosin concentration
Ramy czasowe: At the single study visit (Day 1)

Fasting serum asprosin concentration measured by enzyme-linked immunosorbent assay, compared between women with metabolic syndrome and healthy controls. Reported in ng/mL.
At the single study visit (Day 1)
Expression of selected circulating microRNAs
Ramy czasowe: At the single study visit (Day 1)

Relative expression of six circulating microRNAs (miR-15a-5p, miR-197-3p, miR-23a-3p, miR-21-5p, miR-146a-5p, miR-223-3p) quantified in plasma by reverse-transcription quantitative PCR. Expression is normalized using ath-miR159a as an exogenous spike-in control and hsa-miR-186-5p as a reference. All six analytes are measured by the same method and reported in the same unit of measure, relative fold change, with results reported separately for each microRNA.
At the single study visit (Day 1)

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Prevalence of individual metabolic syndrome components
Ramy czasowe: At the single study visit (Day 1)

Proportion of participants in each group meeting each of the five NCEP ATP III components: elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, elevated fasting glucose, and abdominal obesity. Reported as percentage of participants.
At the single study visit (Day 1)
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Ramy czasowe: At the single study visit (Day 1)

HOMA-IR calculated from fasting glucose and fasting insulin as (fasting insulin in microU/mL x fasting glucose in mg/dL) / 405, compared between the metabolic syndrome group and the control group. Reported as an index score (unitless). Higher values indicate greater insulin resistance.
At the single study visit (Day 1)
Castelli Risk Index I
Ramy czasowe: At the single study visit (Day 1)

Ratio of total cholesterol to HDL cholesterol, calculated from the fasting lipid profile and compared between the metabolic syndrome group and the control group. Reported as a ratio (unitless). Higher values indicate greater atherogenic risk.
At the single study visit (Day 1)
Body fat percentage
Ramy czasowe: At the single study visit (Day 1)

Body fat percentage (PBF) measured by bioelectrical impedance analysis, compared between the metabolic syndrome group and the control group. Reported as a percentage of total body mass.
At the single study visit (Day 1)
Serum brain-derived neurotrophic factor (BDNF) concentration
Ramy czasowe: At the single study visit (Day 1)

Fasting serum BDNF concentration measured by enzyme-linked immunosorbent assay, compared between groups and correlated with metabolic syndrome components. Reported in ng/mL.
At the single study visit (Day 1)
Serum cortisol concentration
Ramy czasowe: At the single study visit (Day 1)

Fasting serum cortisol concentration measured by immunoassay, compared between groups and correlated with perceived stress and sleep quality scores. Reported in micrograms/dL.
At the single study visit (Day 1)
Quantitative Insulin Sensitivity Check Index (QUICKI)
Ramy czasowe: At the single study visit (Day 1)

QUICKI calculated from fasting glucose and fasting insulin as 1 / (log fasting insulin in microU/mL + log fasting glucose in mg/dL), compared between the metabolic syndrome group and the control group. Reported as an index score (unitless). Higher values indicate greater insulin sensitivity.
At the single study visit (Day 1)
Metabolic Score for Insulin Resistance (METS-IR)
Ramy czasowe: At the single study visit (Day 1)

METS-IR calculated from fasting glucose, fasting triglycerides, body mass index and HDL cholesterol, compared between the metabolic syndrome group and the control group. Reported as an index score (unitless). Higher values indicate greater insulin resistance.
At the single study visit (Day 1)
Triglyceride-Glucose Index (TyG)
Ramy czasowe: At the single study visit (Day 1)

TyG index calculated as the natural logarithm of (fasting triglycerides in mg/dL x fasting glucose in mg/dL) / 2, compared between the metabolic syndrome group and the control group. Reported as an index score (unitless). Higher values indicate greater insulin resistance.
At the single study visit (Day 1)
Castelli Risk Index II
Ramy czasowe: At the single study visit (Day 1)

Ratio of LDL cholesterol to HDL cholesterol, calculated from the fasting lipid profile and compared between the metabolic syndrome group and the control group. Reported as a ratio (unitless). Higher values indicate greater atherogenic risk.
At the single study visit (Day 1)
Atherogenic Index of Plasma (AIP)
Ramy czasowe: At the single study visit (Day 1)

Base-10 logarithm of the ratio of fasting triglycerides to HDL cholesterol, both expressed in mmol/L, compared between the metabolic syndrome group and the control group. Reported as a log-transformed ratio (unitless). Higher values indicate greater atherogenic risk.
At the single study visit (Day 1)
Fat-free mass
Ramy czasowe: At the single study visit (Day 1)

Fat-free mass (FFM) measured by bioelectrical impedance analysis, compared between the metabolic syndrome group and the control group. Reported in kilograms.
At the single study visit (Day 1)
Body Mass Index (BMI)
Ramy czasowe: At the single study visit (Day 1)

Body mass index calculated as body mass in kilograms divided by the square of body height in metres, compared between the metabolic syndrome group and the control group. Reported in kg/m^2.
At the single study visit (Day 1)
Waist-to-Hip Ratio (WHR)
Ramy czasowe: At the single study visit (Day 1)

Ratio of waist circumference to hip circumference, both measured in centimetres with an anthropometric tape, compared between the metabolic syndrome group and the control group. Reported as a ratio (unitless).
At the single study visit (Day 1)
Waist-to-Height Ratio (WHtR)
Ramy czasowe: At the single study visit (Day 1)

Ratio of waist circumference to body height, both measured in centimetres, compared between the metabolic syndrome group and the control group. Reported as a ratio (unitless).
At the single study visit (Day 1)
A Body Shape Index (ABSI)
Ramy czasowe: At the single study visit (Day 1)

ABSI calculated from waist circumference, body mass index and body height according to Krakauer and Krakauer, compared between the metabolic syndrome group and the control group. Reported as an index score. Higher values indicate greater central adiposity relative to body size.
At the single study visit (Day 1)
Hip Index (HI)
Ramy czasowe: At the single study visit (Day 1)

Hip Index calculated from hip circumference adjusted for body height and body mass, compared between the metabolic syndrome group and the control group. Reported as an index score.
At the single study visit (Day 1)
Body Adiposity Index (BAI)
Ramy czasowe: At the single study visit (Day 1)

BAI calculated from hip circumference and body height, compared between the metabolic syndrome group and the control group. Reported as estimated body fat expressed as a percentage of total body mass.
At the single study visit (Day 1)
Visceral Adiposity Index (VAI)
Ramy czasowe: At the single study visit (Day 1)

VAI calculated from waist circumference, body mass index, fasting triglycerides and HDL cholesterol using the sex-specific formula for women, compared between the metabolic syndrome group and the control group. Reported as an index score (unitless).
At the single study visit (Day 1)
Lipid Accumulation Product (LAP)
Ramy czasowe: At the single study visit (Day 1)

LAP calculated for women as (waist circumference in cm minus 58) multiplied by fasting triglycerides in mmol/L, compared between the metabolic syndrome group and the control group. Reported in cm x mmol/L.
At the single study visit (Day 1)

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Physical activity level assessed by the International Physical Activity Questionnaire (IPAQ)
Ramy czasowe: At the single study visit (Day 1)

Habitual physical activity assessed using the International Physical Activity Questionnaire, compared between the metabolic syndrome group and the control group. Reported as total physical activity in MET-minutes per week. Higher values indicate a higher level of physical activity.
At the single study visit (Day 1)
Sleep quality
Ramy czasowe: At the single study visit (Day 1)

Sleep quality assessed using the Pittsburgh Sleep Quality Index (PSQI). Global score range 0 to 21; higher scores indicate worse sleep quality, with a score above 5 indicating poor sleep quality.
At the single study visit (Day 1)
Perceived stress level
Ramy czasowe: At the single study visit (Day 1)

Perceived stress assessed using the 10-item Perceived Stress Scale (PSS-10). Score range 0 to 40; higher scores indicate higher perceived stress.
At the single study visit (Day 1)
Daily energy intake
Ramy czasowe: At the single study visit (Day 1)

Habitual daily energy intake assessed using a Food Frequency Questionnaire or the KomPAN questionnaire together with the Fitatu dietary application, compared between the metabolic syndrome group and the control group. Reported in kilocalories per day.
At the single study visit (Day 1)
Health-related quality of life
Ramy czasowe: At the single study visit (Day 1)

Health-related quality of life assessed using the Short Form-36 Health Survey (SF-36). Domain and summary scores range 0 to 100; higher scores indicate better perceived health.
At the single study visit (Day 1)
Waist circumference
Ramy czasowe: At the single study visit (Day 1)

Waist circumference measured with an anthropometric tape according to standard protocol, compared between the metabolic syndrome group and the control group. Reported in centimetres.
At the single study visit (Day 1)
Abdominal circumference
Ramy czasowe: At the single study visit (Day 1)

Abdominal circumference measured with an anthropometric tape at the level of the umbilicus, compared between the metabolic syndrome group and the control group. Reported in centimetres.
At the single study visit (Day 1)
Hip circumference
Ramy czasowe: At the single study visit (Day 1)

Hip circumference measured with an anthropometric tape at the level of the greatest gluteal protrusion, compared between the metabolic syndrome group and the control group. Reported in centimetres.
At the single study visit (Day 1)
Body mass
Ramy czasowe: At the single study visit (Day 1)

Body mass measured on a calibrated scale integrated with the bioelectrical impedance analyser, compared between groups. Reported in kilograms.
At the single study visit (Day 1)
Target body mass
Ramy czasowe: At the single study visit (Day 1)

Target body mass calculated by the bioelectrical impedance analyser from measured body composition, compared between groups. Reported in kilograms.
At the single study visit (Day 1)
Fat mass
Ramy czasowe: At the single study visit (Day 1)

Mass of body fat (MBF) measured by bioelectrical impedance analysis, compared between groups. Reported in kilograms.
At the single study visit (Day 1)
Soft lean mass
Ramy czasowe: At the single study visit (Day 1)

Soft lean mass (SLM) measured by bioelectrical impedance analysis, compared between groups. Reported in kilograms.
At the single study visit (Day 1)
Skeletal muscle mass
Ramy czasowe: At the single study visit (Day 1)

Skeletal muscle mass (SMM) measured by bioelectrical impedance analysis, compared between groups. Reported in kilograms.
At the single study visit (Day 1)
Total body water
Ramy czasowe: At the single study visit (Day 1)

Total body water (TBW) measured by bioelectrical impedance analysis, compared between groups. Reported as a percentage of total body mass.
At the single study visit (Day 1)
Extracellular water ratio
Ramy czasowe: At the single study visit (Day 1)

Ratio of extracellular water to total body water (ECW ratio) measured by bioelectrical impedance analysis, compared between groups. Reported as a ratio (unitless).
At the single study visit (Day 1)
Body cell mass
Ramy czasowe: At the single study visit (Day 1)

Body cell mass (BCM) measured by bioelectrical impedance analysis, compared between groups. Reported in kilograms.
At the single study visit (Day 1)
Protein content
Ramy czasowe: At the single study visit (Day 1)

Total body protein content measured by bioelectrical impedance analysis, compared between groups. Reported in kilograms.
At the single study visit (Day 1)
Mineral content
Ramy czasowe: At the single study visit (Day 1)

Total body mineral content measured by bioelectrical impedance analysis, compared between groups. Reported in kilograms.
At the single study visit (Day 1)
Physical activity energy expenditure assessed by the 7-day Physical Activity Recall (7day-PAR)
Ramy czasowe: At the single study visit (Day 1)

Physical activity energy expenditure over the preceding seven days assessed using the 7-day Physical Activity Recall interview, compared between the metabolic syndrome group and the control group. Reported as mean daily energy expenditure in kilocalories per day.
At the single study visit (Day 1)
Macronutrient distribution of the diet
Ramy czasowe: At the single study visit (Day 1)

Contribution of protein, fat and carbohydrate to total daily energy intake, assessed using a Food Frequency Questionnaire or the KomPAN questionnaire together with the Fitatu dietary application, compared between the metabolic syndrome group and the control group. Reported as a percentage of total daily energy intake for each macronutrient.
At the single study visit (Day 1)

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

University of Applied Sciences in Nowy Targ

Współpracownicy

University of Physical Education in Krakow, Poland
Maj Institute of Pharmacology, Polish Academy of Sciences (CEPHARES), Poland

Śledczy

  • Główny śledczy: Małgorzata Kantorowicz, Ph. D., University of Applied Sciences in Nowy Targ

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Przydatne linki

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 listopada 2026

Zakończenie podstawowe (Szacowany)

1 marca 2027

Ukończenie studiów (Szacowany)

1 marca 2027

Daty rejestracji na studia

Pierwszy przesłany

16 października 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

3 listopada 2026

Pierwszy wysłany (Rzeczywisty)

4 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

4 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

3 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • SKN/SP/659046/2026
  • SKN/SP/659046/2026 (Inny numer grantu/finansowania: Ministry of Science and Higher Education, Poland)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Opis planu IPD

Individual participant data will not be made publicly available. Data are collected under informed consent that specifies use for scientific purposes following anonymization, and the consent does not cover open data sharing. Anonymized aggregate results will be published in a peer-reviewed scientific journal. Requests for anonymized data may be directed to the principal investigator and will be considered subject to approval by the sponsor institution and the bioethics committee.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj